 Jeffrey Schowinsky
Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 8 | 2024 | 652 | 0.830 |
Why?
| | Mycosis Fungoides | 2 | 2018 | 62 | 0.610 |
Why?
| | Azacitidine | 4 | 2023 | 150 | 0.540 |
Why?
| | Brain Neoplasms | 3 | 2018 | 1305 | 0.540 |
Why?
| | HMGA2 Protein | 1 | 2015 | 8 | 0.460 |
Why?
| | Lipomatosis | 1 | 2015 | 5 | 0.460 |
Why?
| | Adamantinoma | 1 | 2015 | 4 | 0.460 |
Why?
| | Synovial Membrane | 1 | 2015 | 121 | 0.420 |
Why?
| | Tibia | 1 | 2015 | 183 | 0.400 |
Why?
| | Eosinophilia | 1 | 2015 | 226 | 0.400 |
Why?
| | Keratins | 3 | 2026 | 173 | 0.400 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2017 | 913 | 0.390 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2012 | 20 | 0.370 |
Why?
| | Skin Neoplasms | 2 | 2018 | 857 | 0.360 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2012 | 79 | 0.340 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 6 | 2023 | 253 | 0.330 |
Why?
| | Sulfonamides | 6 | 2023 | 567 | 0.290 |
Why?
| | Soft Tissue Neoplasms | 2 | 2023 | 120 | 0.290 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1793 | 0.280 |
Why?
| | Dendritic Cell Sarcoma, Follicular | 1 | 2026 | 4 | 0.240 |
Why?
| | Epithelioid Cells | 1 | 2026 | 10 | 0.240 |
Why?
| | Clonal Evolution | 2 | 2017 | 45 | 0.240 |
Why?
| | Pleural Neoplasms | 1 | 2026 | 27 | 0.240 |
Why?
| | Biopsy, Needle | 1 | 2006 | 187 | 0.240 |
Why?
| | Diagnostic Errors | 1 | 2006 | 178 | 0.230 |
Why?
| | Rectum | 1 | 2006 | 192 | 0.220 |
Why?
| | Tissue Scaffolds | 1 | 2024 | 213 | 0.190 |
Why?
| | Carrier Proteins | 2 | 2017 | 748 | 0.180 |
Why?
| | Nuclear Proteins | 2 | 2017 | 719 | 0.170 |
Why?
| | Surgical Wound Infection | 1 | 2024 | 321 | 0.170 |
Why?
| | Mastocytosis, Cutaneous | 1 | 2021 | 5 | 0.170 |
Why?
| | Mastocytosis | 1 | 2021 | 12 | 0.170 |
Why?
| | Biomarkers, Tumor | 3 | 2026 | 1258 | 0.160 |
Why?
| | Extracellular Matrix | 1 | 2024 | 556 | 0.160 |
Why?
| | Adenocarcinoma | 1 | 2006 | 896 | 0.150 |
Why?
| | Prostatic Neoplasms | 1 | 2006 | 1049 | 0.140 |
Why?
| | Fatal Outcome | 2 | 2018 | 309 | 0.140 |
Why?
| | Humans | 28 | 2026 | 141754 | 0.140 |
Why?
| | Tetrahydronaphthalenes | 1 | 2017 | 30 | 0.130 |
Why?
| | Valine | 1 | 2017 | 77 | 0.130 |
Why?
| | Leukemia, Neutrophilic, Chronic | 1 | 2017 | 5 | 0.130 |
Why?
| | Receptors, Colony-Stimulating Factor | 1 | 2017 | 7 | 0.130 |
Why?
| | Pyrazoles | 2 | 2021 | 482 | 0.130 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2017 | 79 | 0.130 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 51 | 0.130 |
Why?
| | Immunohistochemistry | 2 | 2026 | 1739 | 0.130 |
Why?
| | Giant Cell Tumor of Bone | 1 | 2016 | 6 | 0.130 |
Why?
| | Genetic Association Studies | 1 | 2018 | 375 | 0.130 |
Why?
| | Skull Base Neoplasms | 1 | 2016 | 31 | 0.120 |
Why?
| | Mutation | 3 | 2017 | 4015 | 0.120 |
Why?
| | Neoplasms, Plasma Cell | 1 | 2015 | 6 | 0.120 |
Why?
| | Leukocytosis | 1 | 2015 | 33 | 0.120 |
Why?
| | Gene Frequency | 1 | 2017 | 494 | 0.120 |
Why?
| | Lymphoma | 1 | 2017 | 228 | 0.120 |
Why?
| | Magnetic Resonance Imaging | 4 | 2016 | 3737 | 0.120 |
Why?
| | Neoplasm, Residual | 3 | 2023 | 132 | 0.110 |
Why?
| | Lipoma | 1 | 2015 | 16 | 0.110 |
Why?
| | Tenosynovitis | 1 | 2015 | 12 | 0.110 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 261 | 0.110 |
Why?
| | Natalizumab | 2 | 2012 | 40 | 0.110 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 289 | 0.110 |
Why?
| | Middle Aged | 9 | 2026 | 34647 | 0.110 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2020 | 833 | 0.110 |
Why?
| | Diagnosis, Differential | 3 | 2026 | 1502 | 0.100 |
Why?
| | Tissue Culture Techniques | 1 | 2013 | 82 | 0.100 |
Why?
| | Male | 14 | 2026 | 70179 | 0.100 |
Why?
| | Genomic Instability | 1 | 2013 | 58 | 0.100 |
Why?
| | Induction Chemotherapy | 2 | 2024 | 80 | 0.100 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 1 | 2012 | 19 | 0.090 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2012 | 38 | 0.090 |
Why?
| | Membrane Glycoproteins | 1 | 2015 | 502 | 0.090 |
Why?
| | Female | 14 | 2026 | 75943 | 0.090 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2018 | 334 | 0.090 |
Why?
| | Ki-67 Antigen | 1 | 2012 | 111 | 0.090 |
Why?
| | CD3 Complex | 1 | 2012 | 106 | 0.090 |
Why?
| | Prognosis | 4 | 2024 | 4080 | 0.090 |
Why?
| | Leukocyte Count | 2 | 2024 | 328 | 0.080 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2015 | 364 | 0.080 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1474 | 0.080 |
Why?
| | Immunologic Factors | 1 | 2012 | 249 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2375 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 1078 | 0.080 |
Why?
| | Neutrophils | 1 | 2015 | 1282 | 0.080 |
Why?
| | Antineoplastic Agents | 2 | 2017 | 2169 | 0.070 |
Why?
| | Lymphatic Diseases | 1 | 2008 | 22 | 0.070 |
Why?
| | Membrane Proteins | 1 | 2015 | 1158 | 0.070 |
Why?
| | Bone Marrow | 3 | 2017 | 302 | 0.070 |
Why?
| | Neutropenia | 1 | 2008 | 157 | 0.070 |
Why?
| | Adult | 8 | 2024 | 39391 | 0.070 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2007 | 59 | 0.070 |
Why?
| | Racemases and Epimerases | 1 | 2006 | 11 | 0.060 |
Why?
| | Chromosome Aberrations | 2 | 2018 | 160 | 0.060 |
Why?
| | Pleura | 1 | 2026 | 27 | 0.060 |
Why?
| | Retrospective Studies | 5 | 2024 | 16374 | 0.060 |
Why?
| | Mucins | 1 | 2006 | 75 | 0.060 |
Why?
| | Aged | 6 | 2024 | 24746 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 2 | 2016 | 2765 | 0.060 |
Why?
| | Prostate-Specific Antigen | 1 | 2006 | 166 | 0.060 |
Why?
| | Treatment Outcome | 4 | 2024 | 11181 | 0.060 |
Why?
| | Hyphae | 1 | 2024 | 11 | 0.060 |
Why?
| | Carcinoma, Renal Cell | 1 | 2007 | 225 | 0.060 |
Why?
| | Biopsy | 2 | 2018 | 1083 | 0.050 |
Why?
| | Antigens, CD34 | 1 | 2023 | 89 | 0.050 |
Why?
| | Cytodiagnosis | 1 | 2023 | 32 | 0.050 |
Why?
| | Fungi | 1 | 2024 | 152 | 0.050 |
Why?
| | Biopsy, Fine-Needle | 1 | 2023 | 70 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2021 | 7923 | 0.050 |
Why?
| | Kidney Neoplasms | 1 | 2007 | 408 | 0.050 |
Why?
| | Disease Progression | 2 | 2023 | 2800 | 0.050 |
Why?
| | World Health Organization | 1 | 2023 | 126 | 0.050 |
Why?
| | Wound Healing | 1 | 2024 | 350 | 0.040 |
Why?
| | Liver Neoplasms | 1 | 2007 | 741 | 0.040 |
Why?
| | Intestinal Mucosa | 1 | 2006 | 632 | 0.040 |
Why?
| | Triazines | 1 | 2021 | 45 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2018 | 1197 | 0.040 |
Why?
| | Pyrroles | 1 | 2021 | 210 | 0.040 |
Why?
| | Young Adult | 3 | 2024 | 13749 | 0.040 |
Why?
| | Neoplastic Stem Cells | 1 | 2023 | 408 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2019 | 5212 | 0.040 |
Why?
| | Remission Induction | 1 | 2019 | 309 | 0.040 |
Why?
| | Karyotyping | 1 | 2018 | 104 | 0.040 |
Why?
| | Histocytochemistry | 1 | 2018 | 80 | 0.040 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2024 | 671 | 0.030 |
Why?
| | Temporomandibular Joint | 1 | 2016 | 10 | 0.030 |
Why?
| | Genetic Testing | 1 | 2019 | 463 | 0.030 |
Why?
| | Occipital Bone | 1 | 2016 | 18 | 0.030 |
Why?
| | Sphenoid Bone | 1 | 2016 | 17 | 0.030 |
Why?
| | Frontal Bone | 1 | 2016 | 21 | 0.030 |
Why?
| | Cranial Fossa, Middle | 1 | 2016 | 17 | 0.030 |
Why?
| | Temporal Bone | 1 | 2016 | 44 | 0.030 |
Why?
| | Nitriles | 1 | 2017 | 188 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 310 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2016 | 219 | 0.030 |
Why?
| | Administration, Oral | 1 | 2017 | 803 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 311 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 398 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 1111 | 0.030 |
Why?
| | Karyotype | 1 | 2013 | 17 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1057 | 0.030 |
Why?
| | Pyrimidines | 1 | 2017 | 512 | 0.020 |
Why?
| | Heterografts | 1 | 2013 | 134 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2013 | 250 | 0.020 |
Why?
| | Chondrogenesis | 1 | 2013 | 87 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2013 | 327 | 0.020 |
Why?
| | Carcinogenesis | 1 | 2013 | 215 | 0.020 |
Why?
| | Mice, Nude | 1 | 2013 | 691 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2017 | 919 | 0.020 |
Why?
| | Infant | 2 | 2018 | 9843 | 0.020 |
Why?
| | Genetic Variation | 1 | 2013 | 1000 | 0.020 |
Why?
| | Leukocyte Elastase | 1 | 2008 | 79 | 0.020 |
Why?
| | Cytokines | 1 | 2015 | 2100 | 0.020 |
Why?
| | Multiple Sclerosis | 1 | 2012 | 470 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 6966 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2012 | 918 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2013 | 2506 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2013 | 2006 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 3495 | 0.010 |
Why?
| | Brain | 1 | 2012 | 2868 | 0.010 |
Why?
| | Adolescent | 1 | 2017 | 22130 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2008 | 6289 | 0.010 |
Why?
| | Mice | 1 | 2013 | 18109 | 0.010 |
Why?
| | Animals | 1 | 2013 | 37749 | 0.010 |
Why?
| | Child | 1 | 2008 | 22414 | 0.000 |
Why?
|
|
Schowinsky's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|